Nightstar Therapeutics, based on Oxford research, stands to receive $800m from Biogen in an acquisition deal that comes a year and a half after completing a $75m IPO.

There is often a lot of media buzz around a company going public and understandably so as it represents a significant milestone. Some initial public offerings are more successful than others and not always do the proceeds exceed the amount a company had collected in venture funding, but the capital may be of secondary interest…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.